DUBLIN :A diversified biopharmaceutical company Theravance Biopharma recently added a new member to their board of director. Theravance Biopharma, primarily focused on the discovery, development and commercialization of organ-selective medicines. The companies soul purpose is to create transformational medicines to improve the lives of patients suffering from serious illnesses. Their research is focused in the areas of inflammation and immunology.
Earlier this week Theravance Biopharma announced the appointment of Deepika R. Pakianathan, Ph.D. to its Board of Directors. Since 2001, Dr. Pakianathan has served as a Managing Member at Delphi Ventures, a venture capital firm focused on biotechnology and medical device investments and leads the firm’s biotechnology investment activities.
“We are honored to welcome Dr. Pakianathan to our board of directors,” said Rick E Winningham, Chief Executive Officer. “We believe her vast experience in the biotechnology sector, translating breakthrough science and taking important therapies from pipeline to patients, will further enhance our already talented Board of Directors.”
Prior to joining Delphi, Dr. Pakianathan was a Vice President in the healthcare group at J.P. Morgan where she was involved in several large healthcare M&A transactions and led public offerings for biotechnology companies. Prior to that, she was a biotechnology research analyst at Genesis Merchant Group. She worked as a postdoctoral scientist in the Immunology Department at Genentech Corporation from 1993 to 1997.
“I am excited to join the Theravance Biopharma board, which features a roster of high caliber expertise from within the biotechnology industry. The company is at a critical point in its growth and I look forward to helping the company navigate its catalyst-rich future,” said Dr. Pakianathan.
Dr. Pakianathan received her Ph.D. and M.S. from Wake Forest University and her MSc and BSc from the University of Bombay. Dr. Pakianathan also currently serves on the boards of Calithera Biosciences, Inc., Karyopharm Therapeutics, Inc., and Mereo BioPharma Group, PLC.
Theravance Biopharma applies organ-selective expertise to biologically compelling targets to discover and develop medicines designed to treat underserved localized diseases and to limit systemic exposure, in order to maximize patient benefit and minimize risk. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Their pipeline of internally discovered programs is targeted to address significant patient needs.